The in vitro activities of LY-303366, a new semisynthetic echinocandin, and comparators amphotericin B, 5-fluorocytosine, fluconazole, and ketoconazole against 205 systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species were determined. LY-303366 had MICs of <0.32 g/ml for all Candida albicans (n ‫؍‬ 99), Candida glabrata (n ‫؍‬ 18), and Candida tropicalis (n ‫؍‬ 10) isolates tested. LY-303366 was also active against Aspergillus species (minimum effective concentration at which 90% of the isolates are inhibited, 0.02 g/ml) (n ‫؍‬ 20), was less active against Candida parapsilosis (MIC at which 90% of the isolates are inhibited [MIC 90 ], 5.12 g/ml) (n ‫؍‬ 10), and was inactive against C. neoformans (MIC 90 , >10.24 g/ml) (n ‫؍‬ 15) and B. dermatitidis (MIC 90 , 16 g/ml) (n ‫؍‬ 29).
The incidence of systemic fungal infections has increased dramatically over the past 20 years (1, 5) . Only a limited number of antifungal agents are currently available to treat these infections. Polyenes and azoles, although useful, possess certain limitations. Amphotericin B is often effective but is a parenteral agent with significant toxicity (5) . Azoles demonstrate a limited spectrum of activity, and isolates resistant to their action are increasingly being reported (5, 15) . The development of new antifungal agents, preferably with novel mechanisms of action, that address these deficiencies is therefore imperative.
Echinocandins are lipopeptide antifungal agents that are potent noncompetitive inhibitors of (1,3)-␤-D-glucan synthase, an enzyme essential to the structural integrity of the fungal cell wall (3, 6) . LY-303366 is a synthetic derivative of echinocandin B, a naturally occurring lipopeptide, that possesses both increased lipophilicity and antifungal activity compared with its parent compound (3, 6) . In this report, we assessed the in vitro activity of LY-303366 and comparators amphotericin B, flucytosine (5FC), fluconazole, and ketoconazole against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.
(This work was presented in part at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La., 15 to 18 September 1996.) LY-303366 was supplied by Eli Lilly (Indianapolis, Ind.), amphotericin B was supplied by Bristol-Myers Squibb (SaintLaurent, Canada), 5FC was supplied by Hoffman-La Roche (Mississauga, Canada), fluconazole was supplied by Pfizer Canada (Kirkland, Canada), and ketoconazole was supplied by Janssen/Ortho (North York, Canada). Stock solutions of LY-303366, amphotericin B, fluconazole, and ketoconazole were prepared in dimethyl sulfoxide, and stock solutions of 5FC were prepared in water. The MIC doubling dilution ranges tested were 0.0006 to 10.24 g/ml (Candida species, C. neoformans, and Aspergillus) and 1 to 64 g/ml (B. dermatitidis) for LY-303366, 0.0313 to 16 g/ml for amphotericin B, 0.0156 to 64 g/ml for 5FC, 0.0625 to 128 g/ml for fluconazole, and 0.0039 to 16 g/ml for ketoconazole.
A Candida species, C. neoformans, and B. dermatitidis isolates were subcultured onto Sabouraud agar, and Aspergillus species were cultured onto Sabouraud dextrose agar (SDA) prior to antifungal susceptibility testing. Candida species and C. neoformans antifungal MICs were determined by the National Committee for Clinical Laboratory Standards M27-T macrodilution reference method (11) . Susceptibility testing of B. dermatitidis (yeast phase) and Aspergillus species was performed by the same method. Aspergillus species suspensions were prepared from mature cultures grown on SDA at 30ЊC. SDA slants were flooded with 1 ml of sterile water and gently rocked. The homogeneous supernatant containing Aspergillus conidia was removed and adjusted spectrophotometrically to 82 to 85% transmission at 530 nm. The suspension was then diluted in RPMI 1640 broth to yield a final inoculum of 0.5 ϫ 10 3 to 2.5 ϫ 10 3 CFU/ml. C. albicans ATCC 90028, C. neoformans ATCC 90112, and C. glabrata ATCC 90030 were simultaneously tested with clinical isolates as quality control organisms (11) .
MIC endpoints were determined for amphotericin B, 5FC, fluconazole, and ketoconazole as recommended by the National Committee for Clinical Laboratory Standards M27-T reference method (11) . LY-303366 MICs were defined as the lowest concentration of LY-303366 that inhibited 100% of visible growth. MICs for Candida species were read after 48 h of incubation at 35ЊC, MICs for C. neoformans were read after 72 h of incubation at 35ЊC, MICs for B. dermatitidis were read after 96 to 120 h of incubation at 30ЊC, and MICs and minimum effective concentrations (MECs) for Aspergillus species were read after 48 h of incubation at 30ЊC. Aspergillus species demonstrate two distinct endpoints when their echinocandin or pneumocandin susceptibilities are tested (9) . The first endpoint, the MEC, represents an abrupt transition from test tubes containing a hyphal mass to test tubes containing small, distinct spherical colonies (9) . The second endpoint, the MIC, is found at higher echinocandin and pneumocandin concentrations and is the concentration that prevents visible colony growth (9) . The MEC has been demonstrated to most closely correlate with the efficacy of lipopeptides such as LY-303366 in animal models of disseminated aspergillosis (9) . Colony counts to confirm initial inocula were performed for each MIC determination except for those for Aspergillus species.
The MICs of LY-303366 were Յ0.32 g/ml for all C. albicans, C. glabrata, and C. tropicalis isolates tested (Table 1) . LY-303366 was as active as ketoconazole and was more active than amphotericin B, 5FC, and fluconazole against C. albicans (Table 1) . LY-303366 was approximately as active as 5FC and was more active than amphotericin B, fluconazole, and ketoconazole against C. glabrata and C. tropicalis and less active than its four comparators against C. parapsilosis (Table 1) .
Two strains each of C. krusei and C. lusitaniae were also tested. The MICs for the two strains of C. krusei, respectively, were as follows: LY-303366, 0.25 and 1.28 g/ml; amphotericin B, 2 g/ml; 5FC, 32 and 16 g/ml; fluconazole, 16 and 32 g/ml; and ketoconazole, 0.0625 and 0.5 g/ml. The MICs for the two strains of C. lusitaniae were as follows: LY-303366, 0.64 g/ml; amphotericin B, 0.25 and 0.5 g/ml, respectively; 5FC, Յ0.0156 g/ml; fluconazole, 0.25 and 2 g/ml, respectively; and ketoconazole, Յ0.0039.
The MICs of fluconazole for three strains of C. tropicalis, seven strains of C. glabrata, and two strains of Candida krusei were Ն16 g/ml. The MICs of LY-303366 for 11 of these 12 strains ranged from 0.08 to 0.32 g/ml. The twelfth strain was a C. krusei strain (fluconazole MIC, 32 g/ml) for which the LY-303366 MIC was 1.28 g/ml. The MIC at which 90% of the isolates are inhibited (MIC 90 ) for these 12 strains was 0.32 g/ml. The LY-303366 MIC 90 for the remaining 18 C. glabrata isolates and C. tropicalis isolates for which the fluconazole MICs were Յ8 g/ml was also 0.32 g/ml. LY-303366 appeared equally active against Candida species for which the fluconazole MICs were Ն16 g/ml and against those for which the fluconazole MICs were Յ8 g/ml.
LY-303366 had significantly less activity against C. neoformans and B. dermatitidis than against C. albicans, C. glabrata, and C. tropicalis (Table 2 ). Ketoconazole and amphotericin B were the most active antifungal agents tested for both C. neoformans and B. dermatitidis (Table 2) . LY-303366 demonstrated potent in vitro activity against Aspergillus species with a MEC 90 of 0.02 g/ml (Table 2) . Ranges for each Aspergillus species are presented in Table 3 . MICs of LY-303366 for the control strain yeast isolates were 0.02 g/ml for C. albicans (12) (13) (14) and in vivo (2, (16) (17) (18) activity against Candida species, Aspergillus species, and Pneumocystis carinii. In vitro studies have demonstrated that LY-303366 is as active as amphotericin B and is more active than 5FC and fluconazole against most Candida species, with less activity against C. parapsilosis and C. lusitaniae (12) (13) (14) . Our work demonstrated similar results (Table  1) . We found that LY-303366 possessed activity against C. albicans, C. glabrata, and C. tropicalis, including strains for which the fluconazole MICs were Ն16 g/ml, at concentrations lower than those achievable in human serum (10) . A recent publication reported that a 500-mg dose of LY-303366 taken orally was safe and produced maximum peak concentrations in serum of approximately 0.75 g/ml with a serum halflife of 30 h (10) . Others have also demonstrated potent in vitro LY-303366 activity against Candida species for which there are elevated fluconazole (Ն128 g/ml) and itraconazole (Ն2 g/ ml) MICs (12) . Similarly, two strains of C. albicans, one for which the fluconazole MIC was Ն128 g/ml and the other for which the fluconazole MIC was 0.5 g/ml, were demonstrated to possess similar LY-303366 killing kinetics and susceptibilities (4). LY-303366 was less active against C. parapsilosis, C. lusitaniae, and one of two strains of C. krusei. Previously, cilofungin (LY-121019), another echinocandin B derivative, was shown to be active against several Candida species but inactive against C. parapsilosis (8).
LY-303366 was not active in vitro against C. neoformans or B. dermatitidis ( Table 2 ). The lack of activity against C. neoformans (7, 13, 14) and B. dermatitidis (7) has been reported previously and may arise because of greater cellular reliance upon ␣-(1-3)-D-glucan linkages and not ␤-(1,3)-D-glucan linkages in cell wall glucan polymers of these fungi (3).
Echinocandin and pneumocandin MECs have been demonstrated to correlate well with in vivo activity (9) . LY-303366 demonstrated potent activity against Aspergillus species, for which the MEC 90 was 0.02 g/ml. This result is in agreement with previously published work reporting a MEC of 0.04 g/ml for a collection of Aspergillus species (13) .
We conclude that LY-303366 has promising antifungal activity for C. albicans, C. glabrata, C. tropicalis, and Aspergillus species. LY-303366 was less active against C. parapsilosis, C. lusitaniae, and C. krusei and was inactive against B. dermatitidis and C. neoformans. Further in vitro and in vivo investigation of LY-303366 is warranted. 
